石药集团明复乐TRACE-III临床研究亮相欧洲卒中大会

中国网财经06-18

在近日于瑞士巴塞尔举行的第十届欧洲卒中大会(ESOC)上，石药集团旗下的明复乐(注射用重组人TNK组织型纤溶酶原激活剂，rhTNK-tPA)TRACE-III临床研究取得了举世瞩目的成果。这项由首都医科大学附属北京天坛医院王拥军教授团队主导的多中心、前瞻性、开放标签、终点盲法、随机对照的IIT临床试验，成功证明了：在发病后4.5至24小时内，对于前循环大动脉闭塞且无法进行血管内治疗的急性缺血性卒中...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2444173558?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-18 12:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444173558","market":"hk","top_or_hot":-1,"title":"石药集团明复乐TRACE-III临床研究亮相欧洲卒中大会","media":"中国网财经","content":"<div>\n<p>在近日于瑞士巴塞尔举行的第十届欧洲卒中大会(ESOC)上，石药集团旗下的明复乐(注射用重组人TNK组织型纤溶酶原激活剂，rhTNK-tPA)TRACE-III临床研究取得了举世瞩目的成果。这项由首都医科大学附属北京天坛医院王拥军教授团队主导的多中心、前瞻性、开放标签、终点盲法、随机对照的IIT临床试验，成功证明了：在发病后4.5至24小时内，对于前循环大动脉闭塞且无法进行血管内治疗的急性缺血性卒中...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202406183106585612.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团明复乐TRACE-III临床研究亮相欧洲卒中大会</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团明复乐TRACE-III临床研究亮相欧洲卒中大会\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 12:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202406183106585612.html><strong>中国网财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在近日于瑞士巴塞尔举行的第十届欧洲卒中大会(ESOC)上，石药集团旗下的明复乐(注射用重组人TNK组织型纤溶酶原激活剂，rhTNK-tPA)TRACE-III临床研究取得了举世瞩目的成果。这项由首都医科大学附属北京天坛医院王拥军教授团队主导的多中心、前瞻性、开放标签、终点盲法、随机对照的IIT临床试验，成功证明了：在发病后4.5至24小时内，对于前循环大动脉闭塞且无法进行血管内治疗的急性缺血性卒中...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202406183106585612.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0067412154.USD","symbol_name":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202406183106585612.html","article_id":"2444173558","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406183106585612.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2444173558","pubTimestamp":1718686076,"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"在近日于瑞士巴塞尔举行的第十届欧洲卒中大会(ESOC)上，石药集团旗下的明复乐(注射用重组人TNK组织型纤溶酶原激活剂，rhTNK-tPA)TRACE-III临床研究取得了举世瞩目的成果。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK4134":"信息科技咨询与其它服务","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","III":"信息服务","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK1515":"抗疫概念","01093":"石药集团","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE0008368742.USD":"首域中国增长基金I Acc"},"translate_title":"CSPC Mingfule TRACE-III clinical research unveiled at the European Stroke Conference","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"01093":1},"content_text":"在近日于瑞士巴塞尔举行的第十届欧洲卒中大会(ESOC)上，石药集团旗下的明复乐(注射用重组人TNK组织型纤溶酶原激活剂，rhTNK-tPA)TRACE-III临床研究取得了举世瞩目的成果。这项由首都医科大学附属北京天坛医院王拥军教授团队主导的多中心、前瞻性、开放标签、终点盲法、随机对照的IIT临床试验，成功证明了：在发病后4.5至24小时内，对于前循环大动脉闭塞且无法进行血管内治疗的急性缺血性卒中患者，使用TNK进行静脉溶栓治疗，能够显著降低患者的残疾率，且安全性和有效性得到验证。 　　TRACE-III试验的公布引发了现场热烈反响，这一成果不仅为急性缺血性卒中患者的治疗带来了新的希望，更标志着石药集团TNK在治疗时间窗上的重大突破。此前，替奈普酶等溶栓药物的临床应用多局限于发病后4.5小时内的黄金时间窗，但TRACE-III试验的成功，将这一时间窗扩展至了24小时内，为更多患者提供了救治的可能。 　　TRACE-III试验的主要纳入标准为发病4.5-24小时内(包括醒后和无目击者卒中)、MRA/CTA提示大动脉(ICA、M1、M2)闭塞且CT、MRI灌注影像提示有可挽救脑组织，但无法进行血管内治疗的急性缺血性卒中患者。研究的关键影像学纳入标准包括梗死核心体积小于70mL、错配比大于等于1.8以及错配体积大于等于15mL。研究的主要结局为90天无残疾(mRS≤1)的比例，而安全性结局则包括90天死亡率、36小时症状性颅内出血率等。 　　在TRACE-III试验中，石药集团的TNK展现出了出色的治疗效果和安全性。试验结果显示，对于符合适应症的患者，使用TNK进行静脉溶栓治疗，能够显著降低患者的残疾率，且未出现显著增加的严重不良反应。这一成果不仅证明了TNK溶栓药在治疗急性缺血性卒中方面的有效性，更展示了其在时间窗扩展方面的巨大潜力。 （文章来源：中国网财经）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444173558"}